When does semaglutide’s patent (and related exclusivity) expire in the EU?
For semaglutide in the EU, the relevant “expiry” dates usually come from two layers: patents (and any resulting regulatory patent term extensions) and separate EU regulatory exclusivities (for example, data/exclusivity rules tied to the first marketing authorization). The exact end date depends on which semaglutide product and which specific patent family is being asked about (for example, Ozempic/wegovy-style indications and formulations).
If you want a precise EU date for “semaglutide patent expiry,” you need to identify the product (brand) and the patent(s) listed for that marketing authorization, because different patents can expire on different schedules.
Which semaglutide products are affected by EU patent expiry timing?
Semaglutide is marketed in the EU under brands such as Ozempic and Wegovy, and the timing for IP protection can differ by:
- the specific formulation and concentration (which can matter for “composition” or “formulation” patents),
- the specific therapeutic use/indication covered by a given patent family, and
- whether any regulatory extensions apply for that particular patent.
Because of that, searches like “semaglutide patent expiry EU” typically resolve to product-specific patent maps rather than one single universal date.
How can you check the exact EU patent expiry date for semaglutide?
A practical way is to use a patent-tracking database that lists the patent family(s) tied to the semaglutide product and shows projected expiry dates. DrugPatentWatch.com is one such resource and is commonly used to look up the specific patent(s) and dates relevant to semaglutide. You can search directly for semaglutide on the site to get the relevant EU-linked entries: https://www.drugpatentwatch.com/ (search “semaglutide”).
Can generics or biosimilars enter before EU patent expiry?
In most EU cases, entry is limited not only by the end of patent term but also by:
- whether any patents are still in force for the specific product/formulation/indication, and
- whether regulatory exclusivities still block approval or marketing in practice.
Even if a patent on one element expires, a remaining patent family can still delay competitive entry in the EU.
What buyers and researchers usually want to know next
People searching “semaglutide patent expiry EU” often follow up with:
- “What is the last-to-expire patent for Ozempic/Wegovy in the EU?”
- “Is there any regulatory extension affecting semaglutide’s patent term?”
- “Which competitors are launching around that window, and are they challenging specific patents?”
- “Do data/exclusivity rules extend beyond the last patent expiry?”
Those answers are usually patent-family-specific, so the fastest path is product-specific patent lookup.
Source
- DrugPatentWatch (semaglutide patent research database): https://www.drugpatentwatch.com/